Anticoagulation in Acute Pulmonary Embolism with Literature Review

Anticoagulation in Acute Pulmonary Embolism

Anticoagulation stands as the cornerstone in the management of acute pulmonary embolism (PE). It not only prevents further thrombus formation but also significantly reduces PE-related morbidity and mortality. This exhaustive guide aims to provide intricate details on anticoagulant agents, focusing on mechanism of action, pharmacokinetics, risk stratification, transition of therapy, and considerations in special populations, among other aspects.

---

Parenteral Anticoagulants

Low-Molecular-Weight Heparin (LMWH) – Enoxaparin

• Mechanism of Action: Enoxaparin primarily inhibits Factor Xa but also has an effect on thrombin (Factor IIa), albeit to a lesser extent. It achieves its anticoagulant effect by binding to antithrombin, thereby accelerating the inhibition of Factor Xa.
• Dosing Strategy: The standard dosing regimen is 1 mg/kg subcutaneously every 12 hours. For patients with a creatinine clearance (CrCl) below 30 mL/min, the dose should be reduced to 1 mg/kg once daily. Weight-adjusted dosing is particularly important in obese patients.
• Pharmacokinetics: Enoxaparin is absorbed rapidly when administered subcutaneously, boasting nearly complete bioavailability. Its half-life ranges between 4-7 hours, and it is predominantly excreted renally. Its longer half-life allows for more convenient dosing schedules compared to UFH.
• Adverse Effects: The primary concern is bleeding, which necessitates regular monitoring of hemoglobin levels and platelet counts. Enoxaparin can also induce heparin-induced thrombocytopenia (HIT), a prothrombotic condition that requires immediate cessation of the drug. Long-term use can lead to osteoporosis.
• Monitoring and Reversal: Anti-factor Xa levels serve as the gold standard for therapeutic monitoring. Protamine sulfate can partially reverse the anticoagulant effects but is generally less effective than its action on UFH.
• Risk Stratification: Enoxaparin is often preferred in moderate to high-risk PE cases, given its more predictable anticoagulant effect and lesser need for continuous monitoring compared to UFH.
• Transition of Therapy: When transitioning to oral anticoagulants like warfarin, an overlap of at least 5 days is recommended until the INR is stable and within the therapeutic range for at least 24 hours.
• Drug Interactions: Enoxaparin can interact with drugs like antiplatelet agents, increasing the risk of bleeding. It can also interact with drugs affecting renal function, as it is primarily renally cleared.
• Special Populations: In elderly patients and those with renal impairment, dose adjustments and close monitoring are vital to prevent adverse effects. Pregnant women may also require dosing adjustments and more frequent monitoring.
• Cost and Accessibility: Enoxaparin is more expensive than UFH, which may be a consideration in resource-limited settings.

Unfractionated Heparin (UFH)

• Mechanism of Action: UFH exerts its anticoagulant effects by binding to antithrombin, thereby accelerating the inhibition of Factor IIa (thrombin) and Factor Xa.
• Dosing Strategy: For treatment of acute DVT, initial IV bolus dosing is 80 units/kg, followed by a continuous infusion starting at 18 units/kg/hr. Adjustments are made based on aPTT or Anti-Xa.
• Dose adjustments can also be made based on anti-Xa levels using specific nomograms, although aPTT monitoring is more common.
• Pharmacokinetics: UFH has a much shorter half-life (1-2 hours) compared to LMWH and is metabolized in the liver. This makes it a safer option for those with renal impairment.
• Adverse Effects: UFH shares similar adverse effects with LMWH, such as bleeding and HIT. However, the risk of osteoporosis is less prominent with UFH due to its shorter half-life and different metabolic pathway.
• Monitoring and Reversal: Continuous aPTT monitoring is essential. Protamine sulfate serves as an effective reversal agent, neutralizing UFH almost completely.
• Risk Stratification: UFH is often reserved for patients with severe renal impairment or those who might require rapid reversal of anticoagulation, such as individuals at high risk for bleeding or those requiring emergent surgery.
• Transition of Therapy: Transition to oral anticoagulants should overlap with UFH therapy until a stable and therapeutic INR is achieved for at least 24 hours.
• Drug Interactions: UFH can interact with other drugs that affect coagulation, like aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), increasing the risk of bleeding.
• Special Populations: UFH is often preferred in patients with severe renal impairment. It’s also the anticoagulant of choice in pregnant women needing therapeutic anticoagulation due to its inability to cross the placenta.
• Cost and Accessibility: UFH is generally cheaper than LMWH but requires more intensive monitoring, which could offset the cost benefits.

 

---

Oral Anticoagulants

Direct Oral Anticoagulants (DOACs)

• Apixaban
  • Mechanism of Action: Apixaban selectively inhibits Factor Xa, disrupting the coagulation cascade and thus exerting anticoagulant effects without the need for a cofactor like antithrombin.
  • Dosing: Initiation with 10 mg twice daily for the first 7 days is recommended, followed by 5 mg twice daily thereafter. For elderly patients or those weighing less than 60 kg, a reduced maintenance dose of 2.5 mg twice daily is advised.
  • Pharmacokinetics: Apixaban has a half-life of approximately 12 hours and is metabolized primarily through the CYP3A4 pathway. It doesn’t require routine monitoring, making it more convenient but less customizable than warfarin.
  • Adverse Effects: Bleeding is the primary concern, requiring vigilance in patient assessment and monitoring. Other less common effects include nausea and mild liver enzyme elevations.
  • Routine monitoring is generally not required for DOACs, but in emergency situations, coagulation assays like anti-Factor Xa levels can be used. Andexanet alfa and Prothrombin complex concentrates are the recommended reversal agents for life-threatening bleeding.
  • Risk Stratification: Apixaban is suitable for a wide range of PE risk categories but is especially beneficial for patients who require long-term anticoagulation due to its favorable safety profile.
  • Transition of Therapy: Direct transition from parenteral anticoagulants like LMWH or UFH can be safely done, without the need for overlap, once their effects have waned.
  • Drug Interactions: Drugs affecting the CYP3A4 enzyme can influence apixaban levels. For example, co-administration with strong CYP3A4 inhibitors like ketoconazole can increase apixaban exposure, increasing the bleeding risk.
  • Special Populations: Apixaban is generally avoided in pregnancy due to limited data. Renal dose adjustments are necessary in severe renal impairment.
  • Cost and Accessibility: Apixaban is considerably more expensive than warfarin but may be cost-effective when considering the reduced need for monitoring.

• Rivaroxaban
  • Mechanism of Action: Similar to apixaban, rivaroxaban is a direct Factor Xa inhibitor that disrupts the coagulation cascade.
  • Dosing: The initial dosing regimen is 15 mg twice daily for the first 21 days, followed by 20 mg once daily for maintenance therapy.
  • Pharmacokinetics: Rivaroxaban has a shorter half-life (7-11 hours) compared to apixaban and is also metabolized by the CYP3A4 system. It has a more rapid onset of action but requires strict adherence to the dosing schedule.
  • Adverse Effects: Besides bleeding, rivaroxaban can also cause gastrointestinal issues and liver enzyme elevations.
  • Monitoring and Reversal: Like apixaban, routine monitoring is generally not required for DOACs, but in emergencies, coagulation assays like anti-Factor Xa levels can be used. Andexanet alfa and Prothrombin complex concentrates are (PCC) the recommended reversal agents for life-threatening bleeding.
  • Risk Stratification: Rivaroxaban is generally used for low to moderate-risk PE cases. Its once-daily dosing makes it convenient but also risky if a dose is missed.
  • Transition of Therapy: Rivaroxaban can be directly substituted for parenteral anticoagulants like LMWH or UFH, without overlap, once their anticoagulant effects have dissipated.
  • Drug Interactions: Strong CYP3A4 inhibitors or inducers can significantly affect rivaroxaban levels, requiring dose adjustments or alternative anticoagulation strategies.
  • Special Populations: Similar to apixaban, rivaroxaban is generally avoided in pregnancy and requires renal dosing adjustments.
  • Cost and Accessibility: Rivaroxaban is also more expensive than warfarin but offers the advantage of less frequent monitoring.

• Dabigatran
  • Mechanism of Action: Dabigatran is a direct thrombin (Factor IIa) inhibitor. It inhibits both free and fibrin-bound thrombin, thus effectively preventing clot extension and new clot formation.
  • Dosing: For the treatment of acute PE, an initial parenteral anticoagulant should be given for at least 5-10 days, followed by Dabigatran 150 mg twice daily.
  • Pharmacokinetics: Dabigatran is unique among the DOACs because it requires prodrug conversion and has a lower bioavailability. It has a half-life of 12-17 hours and is primarily excreted by the kidneys.
  • Adverse Effects: Besides bleeding risks, dabigatran can cause dyspepsia and stomach pain in some patients. It has a similar risk profile for gastrointestinal bleeding compared to other DOACs.
  • Monitoring and Reversal: Routine monitoring is not generally required, but a diluted thrombin time (dTT) can be used in emergencies. Idarucizumab is a specific reversal agent available for dabigatran.
  • Risk Stratification: Dabigatran is used across a range of risk profiles for PE but is particularly useful when a reversible agent is preferred.
  • Transition of Therapy: Dabigatran requires an initial period of parenteral anticoagulation before initiation. There is no need for overlap once the parenteral anticoagulant is discontinued.
  • Drug Interactions: Dabigatran should not be used concurrently with other anticoagulants, and caution should be exercised with antiplatelets or NSAIDs.
  • Special Populations: Dabigatran is contraindicated in patients with severe renal impairment. It is not recommended during pregnancy due to insufficient data.
  • Cost and Accessibility: Dabigatran is relatively expensive compared to warfarin but offers the advantage of no routine monitoring.

• Edoxaban
  • Mechanism of Action: Edoxaban is a direct Factor Xa inhibitor, similar to apixaban and rivaroxaban.
  • Dosing: After at least 5 days of initial treatment with a parenteral anticoagulant, edoxaban can be initiated at a dose of 60 mg once daily.
  • Pharmacokinetics: It has a half-life of approximately 10-14 hours and is 50% renally excreted. The other half undergoes hepatic metabolism.
  • Adverse Effects: Bleeding is the most significant risk, but edoxaban also has a similar side effect profile to other Factor Xa inhibitors, including potential liver enzyme elevations.
  • Monitoring and Reversal: Routine monitoring is not required, but anti-Factor Xa levels can be checked in emergencies. There is currently no specific reversal agent for edoxaban.
  • Risk Stratification: Edoxaban has been shown to be effective across a broad spectrum of patients with PE and is generally considered for those who have received initial parenteral anticoagulation without complications.
  • Transition of Therapy: Edoxaban should be initiated after a minimum of 5 days of parenteral anticoagulation. There’s no need for overlap as edoxaban can be initiated once the parenteral agent is discontinued.
  • Drug Interactions: Edoxaban interacts with drugs that are strong inhibitors or inducers of P-glycoprotein and should be avoided in such combinations.
  • Special Populations: It is not recommended in patients with severe renal or hepatic impairment and should be avoided in pregnancy.
  • Cost and Accessibility: Similar to other DOACs, edoxaban is more expensive upfront compared to warfarin but may be cost-effective when considering the reduced need for monitoring. 

• Vitamin K Antagonists (VKAs) – Warfarin
  • Mechanism of Action: Warfarin inhibits Vitamin K epoxide reductase, an enzyme involved in the regeneration of active Vitamin K. This action depletes functional Vitamin K reserves, thereby inhibiting the synthesis of Vitamin K-dependent clotting factors (II, VII, IX, X).
  • Dosing Strategy: Initial dosing varies between 5-10 mg daily, with subsequent adjustments based on INR levels. The target INR is generally between 2 and 3 for PE treatment.
  • Pharmacokinetics: Warfarin is metabolized by multiple CYP450 enzymes, has a half-life of 36-42 hours, and requires frequent monitoring due to its narrow therapeutic window.
  • Adverse Effects: The primary risk is bleeding, especially when INR exceeds the therapeutic range. Rare but severe adverse effects include skin necrosis and purple toe syndrome.
  • Monitoring and Reversal: Frequent INR monitoring is essential, with dose adjustments made accordingly. Vitamin K serves as the reversal agent for warfarin toxicity, and fresh frozen plasma can be used for immediate reversal in life-threatening bleeds.
  • Risk Stratification: Warfarin is usually reserved for patients who cannot tolerate DOACs or in whom DOACs are contraindicated, such as those with mechanical heart valves.
  • Transition of Therapy: Overlap with parenteral anticoagulation is necessary until a therapeutic INR is maintained for at least 24-48 hours.
  • Drug Interactions: Numerous drug-drug and drug-food interactions exist, including antibiotics that can either potentiate or inhibit its effects.
  • Special Populations: Warfarin is generally avoided in pregnancy, especially during the first trimester and the peripartum period due to its teratogenicity and the risk of fetal bleeding, respectively.
  • Cost and Accessibility: Warfarin is inexpensive but necessitates frequent monitoring, which can be a burden for some patients.

---

Monitoring Parameters

• UFH: Monitor aPTT every 6 hours initially; target range depends on the hospital protocol.
• LMWH: Anti-Factor Xa levels in special populations (e.g., obesity, pregnancy).
• Warfarin: Regular INR monitoring; target 2.0-3.0 for PE.
• DOACs: Periodic renal and liver function tests; specific coagulation tests are not routinely required.

 

Selection of Anticoagulants: Key Considerations

The choice between parenteral agents like UFH or LMWH and oral agents like DOACs or warfarin depends on multiple factors:

• Patient Stability: Unstable patients may benefit from UFH due to its rapid onset and reversibility.
• Renal Function: Renal impairment may influence the choice of anticoagulant and dosing.
• Outpatient vs. Inpatient Treatment: LMWH is often preferred for outpatient treatment.
• Special Populations: LMWH is preferred in pregnancy and cancer-associated PE.
• Patient Preferences: DOACs may offer convenience without routine monitoring.
• Cost Considerations
  • UFH and Warfarin: Generally low cost.
  • LMWH: Moderate cost; varies by brand.
  • DOACs: Typically higher cost, but may be offset by reduced monitoring expenses.

• Drug Interactions: A careful review of other medications may influence the choice of anticoagulant.

---

Summary

This expanded section offers a comprehensive and detailed overview of the anticoagulation options for PE, focusing on dosing, renal adjustments, adverse effects, clinical guidance, and practical considerations. It serves as an essential reference for pharmacists and physicians in individualizing treatment plans for patients with PE.

Tables for Anticoagulants

Table 1: Unfractionated Heparin (UFH)

Standard Dosing	Renal Dose Adjustments	Adverse Effects
IV infusion, adjusted by aPTT	No adjustment	Bleeding, HIT, hyperkalemia

 

Table 2: Low Molecular Weight Heparin (LMWH) – Enoxaparin (Lovenox)

Standard Dosing	Renal Dose Adjustments	Adverse Effects
1 mg/kg SC every 12 hours	1 mg/kg once daily if CrCl <30 mL/min	Bleeding, HIT (lower risk), local reactions

 

Table 3: Direct Oral Anticoagulants (DOACs)

Anticoagulant	Standard Dosing	Renal Dose Adjustments	Adverse Effects
Dabigatran (Pradaxa)	150 mg orally twice daily	CrCl ≤30 mL/minute or on dialysis: Dosing recommendation cannot be provided	Dyspepsia, GI bleeding
Rivaroxaban (Xarelto)	15 mg orally twice daily for 21 days, then 20 mg daily	CrCl <30 mL/min: Avoid	Bleeding, liver enzymes elevation
Apixaban (Eliquis)	10 mg orally twice daily for 7 days, then 5 mg twice daily	No dose adjustment recommended for renal function	Bleeding, nausea
Edoxaban (Savaysa)	60 mg orally once daily after parenteral therapy	30 mg once daily if CrCl 15-50 mL/min CrCl <15 mL/min: use is not recommended	Bleeding, rash

 

Table 4: Warfarin (Coumadin)

Standard Dosing	Renal Dose Adjustments	Adverse Effects
Individualized based on INR	No direct adjustments	Bleeding, skin necrosis

These tables provide a concise summary of the key characteristics of various anticoagulants used in the management of PE. They can be included in the course materials as quick reference guides for clinicians.

---

Guideline Recommendations

ACCP Guidelines (2016)

The American College of Chest Physicians emphasizes the use of DOACs over warfarin in most non-cancer patients (Grade 2B). In cancer-associated PE, LMWH is preferred (Grade 2C). Recommendations include three months of anticoagulation for provoked PE, with extended therapy considered in unprovoked PE if there’s a low bleeding risk (Grade 2B).

ESC Guidelines (2019)

The European Society of Cardiology advocates for DOACs as first-line therapy in non-cancer patients, allowing for more straightforward management. Individualized treatment duration is advised based on risk factors and patient preference. Thrombolytic therapy may be considered in hemodynamically unstable patients, and a patient-centered approach is encouraged.

ASH Guidelines (2020)

The American Society of Hematology underscores shared decision-making in the choice of anticoagulant, often favoring DOACs over VKAs unless contraindicated. The guidelines also contemplate the use of aspirin after completion of anticoagulation in select patients (Grade 2C), emphasizing patient-specific considerations and ongoing reassessment.

NICE Guidelines (2018)

The UK’s National Institute for Health and Care Excellence recommends LMWH followed by VKA or DOAC for provoked PE, with extended anticoagulation in unprovoked PE if the bleeding risk is low. Regular reassessment of bleeding risk and patient preference is key, and a multidisciplinary approach is encouraged.

AHA Guidelines (2015)

The American Heart Association stresses the early initiation of anticoagulation in suspected PE, with a preference for DOACs in eligible patients. The guidelines also consider the use of IVC filters when anticoagulation is contraindicated, reflecting a comprehensive approach to management.

Landmark Trials

RE-COVER and RE-COVER II Trials (Dabigatran)

These trials demonstrated the non-inferiority of dabigatran to warfarin in acute VTE treatment, including PE. Patients were initially treated with a parenteral anticoagulant before transitioning to dabigatran. The trials found similar efficacy and bleeding profiles between the two treatments, establishing dabigatran as a viable alternative to warfarin.

EINSTEIN-PE Trial (Rivaroxaban)

The EINSTEIN-PE trial showcased rivaroxaban’s non-inferiority to the standard treatment of enoxaparin followed by warfarin in acute PE. Rivaroxaban provided a single-drug approach without the need for initial parenteral therapy, simplifying treatment without increased bleeding risk. This has influenced the preference for rivaroxaban in suitable patients.

AMPLIFY Trial (Apixaban)

The AMPLIFY trial established apixaban’s non-inferiority to enoxaparin/warfarin in acute PE treatment, with the added benefit of reduced major bleeding. The simplified treatment regimen of apixaban, without the need for initial parenteral therapy, makes it an attractive option for many patients, balancing efficacy and safety.

Hokusai-VTE Trial (Edoxaban)

The Hokusai-VTE trial demonstrated edoxaban’s non-inferiority to warfarin in treating VTE, including severe PE, with less bleeding. Unlike other DOACs, edoxaban requires initial parenteral therapy, catering to a wide range of patients and clinical scenarios. The trial’s inclusion of severe PE patients adds to its significance in guiding therapy.

---

Non-Pharmacological Therapies

• IVC Filters: These are used in patients who have contraindications to anticoagulation or recurrent PE despite adequate anticoagulation.
• Catheter-Directed Thrombolysis (CDT): This involves the localized delivery of thrombolytic agents directly to the clot, thereby reducing the risk of systemic bleeding.
• Percutaneous Mechanical Thrombectomy: This technique is used when thrombolysis is contraindicated. It mechanically disrupts the clot and may be combined with CDT.
• Surgical Embolectomy: This is a last-resort option for life-threatening PE that is unresponsive to other treatments.
• ECMO: In extreme cases of hemodynamic instability or cardiac arrest, extracorporeal membrane oxygenation (ECMO) can be used for circulatory support.